Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to $28.3 million.

  • Rocket Pharmaceuticals' Accounts Payables fell 2390.06% to $28.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.3 million, marking a year-over-year decrease of 2390.06%. This contributed to the annual value of $37.8 million for FY2024, which is 1738.85% down from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Accounts Payables of $28.3 million as of Q3 2025, which was down 2390.06% from $40.5 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Accounts Payables registered a high of $45.8 million during Q4 2023, and its lowest value of $17.9 million during Q2 2021.
  • In the last 5 years, Rocket Pharmaceuticals' Accounts Payables had a median value of $30.6 million in 2023 and averaged $30.3 million.
  • Data for Rocket Pharmaceuticals' Accounts Payables shows a peak YoY increase of 8689.78% (in 2022) and a maximum YoY decrease of 3960.75% (in 2022) over the last 5 years.
  • Over the past 5 years, Rocket Pharmaceuticals' Accounts Payables (Quarter) stood at $19.6 million in 2021, then skyrocketed by 86.9% to $36.7 million in 2022, then rose by 24.9% to $45.8 million in 2023, then fell by 17.39% to $37.8 million in 2024, then fell by 25.3% to $28.3 million in 2025.
  • Its Accounts Payables stands at $28.3 million for Q3 2025, versus $40.5 million for Q2 2025 and $32.4 million for Q1 2025.